Combination adjunctive nebulized furosemide and salbutamol versus single agent therapy in COPD patients: A randomized controlled trial by Saba, M. et al.
Contents lists available at ScienceDirect
Annals of Medicine and Surgery
journal homepage: www.elsevier.com/locate/amsu
Combination adjunctive nebulized furosemide and salbutamol versus single
agent therapy in COPD patients: A randomized controlled trial
Mohammadali Sabaa, Abdoulhossein Davoodabadib,∗, Azin Ghaffaric, Hamidreza Gilasid,
Babak Haghpanahe
a Department Pulmonary, Shahid Beheshti Hospital, Kashan, Iran
bDepartments of Surgery, Kashan University of Medical Sciences, Kashan, Iran
c Internal Medicine, Shahid Beheshti Hospital, Kashan, Iran
dDepartments of Epidemiology & Biostatistics, Kashan University of Medical Sciences, Kashan, Iran
eOrthopedic Surgery, Kashan University of Medical Sciences, Kashan, Iran







A B S T R A C T
Background: COPD patients often require multiple therapies to enhance their lung function and reduce their
symptoms in exacerbations. This study aimed to investigate the relative effects of combination adjunctive
nebulized furosemide and salbutamol therapy versus single agent treatment in COPD patients.
Methods: Sixty-nine COPD patients were randomly divided into two groups. The first group (G1, 34 cases) re-
ceived salbutamol in their first episode. The second group (G2, 35 cases) received furosemide in their first
episode. Spirometry indices (FEV1, FVC, and FEV1/FVC), mMRC and BORG (COPD assessment) were assessed
and recorded for all patients.
To study the efficacy of combination adjunctive therapy, in 2nd episodes, the nebulized furosemide was
added to nebulized salbutamol in the G1, and nebulized salbutamol was added to nebulized furosemide in G2.
The aforementioned indices were then re-assessed.
Results: The mean age was (64.92 ± 11.71 years, 55% males. The use of nebulized furosemide and salbutamol
as single agents slightly improved the spirometeric parameters, but it was not noteworthy compared to the
significant improvement of the FEV1, FVC, FEV1/FVC, mMRC, and Borg parameters with combination therapy
(p-value<0.001). In the first episode, there was no difference in spirometeric indices, between groups (p-
value > 0.1), so furosemide is considered as effective as nebulized salbutamol. Also, the results of sequential
drugs administration, in the two groups was similar.
Conclusion: Conjunction of nebulized furosemide and salbutamol is more effective than single therapy and can
be considered as preferred drug regimen without any reported side effect in the treatment of COPD.
1. Introduction
1.1. Background and objectives
Chronic obstructive pulmonary disease (COPD) is a poorly re-
versible disease of the lungs, with significant morbidity and mortality
[1,2]. The mortality rates of COPD patients during 1970–2002 have
been doubled [3]. Severe dyspnea, as a dominant symptom, fatigue and
disability, strongly predict impaired physical activity [4,5].
Patients with COPD has a high-risk of short and long-term death and
postoperative infections after thoracic surgery. In patients undergoing
surgery, impaired spirometry indices have been proved to be prognostic
markers and such patients needs more COPD stabilization and careful
monitoring of infection signs [6,7]. Reduction in the tolerance of phy-
sical activity, is the strongest predictor of mortality in COPD patients
[8].
Despite high prevalence of COPD and implementation of many
treatment guidelines, effective management has still remained a chal-
lenge in healthcare fields. Evidence shows that many of the patients do
not received enough treatment [9].
https://doi.org/10.1016/j.amsu.2020.07.005
Received 24 April 2020; Received in revised form 4 July 2020; Accepted 6 July 2020
Abbreviations: COPD, Chronic Obstructive Pulmonary Disease; mMRC, modified Medical Research Council; FEV1, forced expiratory volume/second; FVC, forced
vital capacity
∗ Corresponding author.
E-mail addresses: mohammadali_saba@yahoo.com (M. Saba), davoodabadi28ab@yahoo.com (A. Davoodabadi), azin.ghaffari@yahoo.com (A. Ghaffari),
hrgilasi@yahoo.com (H. Gilasi), babakhp@gmail.com (B. Haghpanah).
Annals of Medicine and Surgery 57 (2020) 85–90
Available online 18 July 2020
2049-0801/ © 2020 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY license 
(http://creativecommons.org/licenses/by/4.0/).
T
Current management of COPD patients is to relieve dyspnea, mini-
mize exacerbations, reducing ventilatory demand, improve exercise
performance, and decrease mortality, which is achieved through pre-
scription of a β2-agonists such as salbutamol [10,11]. Recently, studies
suggest the possible effect of furosemide inhalation in COPD patients,
and improvements in exertional dyspnea and exercise tolerance has
been reported [12]. Nebulized furosemide has been shown to moderate
the activity of sensory afferents in animals’ airways [13], and relieve
sensation of experimentally induced dyspnea by various respiratory
stimuli in healthy humans [14]. On the other hand, inhaled furosemide
has many beneficial effects on the airway epithelium such as im-
provements in exercise induced asthma and inhibition of cough in
asthmatics in healthy volunteers [15–18].
Conjunction of furosemide with salbutamol (as a standard drug)
may be an acceptable therapy and may have promising results in COPD
management in future, however, the clinical evidence to support it as
the standard therapy, is still insufficient [19]. This study is aimed to
investigate the effect of combination adjunctive nebulized furosemide
and salbutamol versus single agent therapy in COPD patients as a
treatment protocol in two separate groups with more attention to their
interactions and combination effects.
To the best of the authors’ knowledge, no study has assessed the
adjunctive effects in pharmaceutical treatment of the stable COPD pa-
tients.
2. Patients and methodology
2.1. Trial design
This study was conducted on stable COPD patients, aged more than
40 years old, in a teaching Hospital from Oct 2018 to Dec 2019
(Research Registry UIN: 5605, institutional ethic committee registra-
tion# 1397.006) and WHO IRCTIRCT201707126187N5. The report is
based in line with the CONSORT criteria [20].
All Spiro metric parameters were obtained by a pulmonologist using
a mass flow spirometer (Ganshorn Medizin Electronic GmbH, Germany)
and were measured according to American Thoracic Society re-
commendations and expressed as absolute values [21]. COPD intensity
was primarily assessed by considering FEV1/FVC ratio as a fixed cut-off
[22]. Then, these ratios were based on grouping the patients as stated
by Global Initiative for Chronic Obstructive Lung Disease (GOLD) [23].
All patients were also evaluated by both modified Medical Research
Council (mMRC) dyspnea scores and Borg scale. mMRC as a clinical
scale of dyspnea estimates the severity of dyspnea in 5 grades (0–4).
Our patients had dyspnea grade of 2–3 according to mMRC [24]. Borg
scale was another tool to measure dyspnea severity and is rated nu-
merically from 0 to 10 [25]. We categorized the scale for dyspnea at the
same time of measuring the spirometry indices (FEV1, FVC, and FEV1/
FVC). The patients in this study were in group 2, 3 of COPD according
to GOLD.
2.2. Inclusion criteria
Stable COPD patients documented by the pulmonologist, (FEV1,
FVC, (FEV1/FVC) less than 70%, irreversible response to inhaled β-
agonist (FEV1increase< 12% and<200 cc after15min from baseline),
symptoms last about 5 years of breathlessness and, productive cough).
2.3. Exclusion criteria
Patients with history of other lung diseases such as pneumonia,
idiopathic pulmonary fibrosis, consolidation, congestive heart failure,
exacerbated, asthma or asthma-COPD overlap. Smoking more than 15
packs/year or, using furosemide and other diuretics also were excluded.
2.4. Sample size calculation
Determined for a one-way comparison of means (matched pairs t-
test) based on a desired statistical power (1 − β) of 0.8 at a level of
0.05. The effect size used in the calculation (f = 0.3) was based on
changes in FEV1 (L) in a prior study [15]). So the number of patients
needed for our experiment was 68 cases.
2.5. Randomization
The patients were randomly divided in Group I and Group II, based
on their reception number.
Nebulizer drug was delivered as aerosols. The patients and the
physicians involved in examination and assessment of the patients were
blind to the type of the drugs administered. We conducted a rando-
mized double-blind, clinical trial in parallel groups for comparing the
efficacy of nebulizer furosemide and nebulized salbutamol each alone
and adjunctive therapy results unstable COPD patients.
2.6. Pere-intervention considerations
All patients were stable so they were instructed to withheld short-
acting β2-agonists (4 h), short-acting anticholinergic (6 h), long-acting
β2-agonists (12 h), long-acting anticholinergic (24 h), short-acting
theophylline (24 h), and long-acting theophylline (48 h) before study
enrollment.
2.7. Intervention
To evaluate the possible interaction between nebulized salbutamol
and nebulized furosemide, two episodes were defined in each group;
the 1st episode implicated the first drug administered alone and the 2nd
episode indicated the effect of combination of the two drugs.
Salbutamol and furosemide were nebulized in doses of 5 mg and
40 mg, respectively, by means of a jet nebulizer (Pari, Sternberg,
Germany). We ensured that none of the patients inhaled any broncho-
dilator or nebulized furosemide for a period 4 h.
Spirometry indices (FEV1, FVC, and FEV1/FVC), mMRC, BORG
scale were measured before the beginning of the first nebulization as
baseline for each group and then after the each administration of the
drugs.
The First Group (G1, 34 cases) received one dose of nebulized sal-
butamol (5 mg) and the second group (G2, 35 cases) received fur-
osemide (40 mg).
For assessment of combination adjunctive efficacy, in 2nd episode
the nebulized furosemide was added to nebulized salbutamol in G1, and
nebulized salbutamol was added to nebulized furosemide in G2.
The study design is presented in Fig. 1.
The study was performed in out pulmonology ward where each
patient was assessed by the same physician before and after interven-
tions in the same day and with the same instruments. Physical activity
was performed to assess the change in BORG or mMRC. According the
Fig. 1. Study design: The yellow show the 1st and red arrows 2nd episodes.
(For interpretation of the references to colour in this figure legend, the reader is
referred to the Web version of this article.)
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mMRC grade before study we asked patients to do the activity at a level
up to the level before study. BORG number was assessed as patients
were exercised by activity question.
2.8. Data collection
Data collection was commenced after study approval and obtaining
informed consent from all participants. During the study period, eligible
cases consecutively were assessed in pulmonology ward each partici-
pant were subjected to measure the spirometry indices (FEV1, FVC, and
FEV1/FVC) and examined mMRC, and Borg as base line and then after
1st and 2nd episode of nebulized drug administration.
2.9. Statistical analysis
A paired sample t-test was used to determine the difference between
episodes within groups. This statistical procedure that is also called the
dependent sample t-test is commonly used to evaluate the mean dif-
ference among two series of observation. The main application of this
strategy is repeated measurement designs, namely at the end of each
process or treatment method [26].
Moreover, a two-sample t-test was applied to compare two episodes
between groups. This approach examines whether the differences in
means between two independent populations is equal to a target value.
An important general application of the method is to investigate if a
new process or treatment option is superior to its current counterpart
[26].
In this study, the results of each episode were compared with the
next episode in a given group and then the two groups were compared
with each other in terms of corresponding episodes. Therefore, the ef-
fects of the two drugs in addition to their individual effects could be
distinguished. The statistical analysis of data was performed using
Minitab v.26 (Minitab Inc., State College, PA, USA) and SPSS v. 23
(IBM, USA) software packages. All results were expressed in means and
standard error and an alpha (α) at 95% confidence interval (p-
value = 0.05) was considered for statistical significance.
2.10. Post-intervention considerations
Standard monitoring of groups was done, concomitant with closed
clinical observation and pulse oximetrp after performing.
Physical activity, and continuing appropriate bronchodilator offered
in each groups until the patients being discharged.
3. Results
Sixty-nine cases were enrolled in this study, mean age was
(64.92 ± 11.71 years), 55(79.7%) of participants were male, demo-
graphics characteristics are summarized in Table 1.
In the both groups, there was no significant difference in sex an age
distribution. The spirometric indices as well as the mMRC and Borg
date in different episodes are presented in Table 2.
The results showed that although all of the parameters improved in
both groups after the first episode of the treatment, the improvement in
pulmonary indices (FEV1, FVC, FEV1/FVC, and MMRC) was not sig-
nificant (p-value > 0.05). Borg scale, however, had a significant im-
provement after the 1st episode (p-value < 0.001). (Table 2).
After the administration of second episode of the treatment, the
FEV1, FVC, FEV1/FVC, MMRC, and Borg parameters, significantly im-
proved in both groups compared to the baseline spirometry indices (p-
value < 0.001). Table 2). The two groups were not significantly dif-
ferent in their response to their 1st and 2nd episode of the treatment (p-
value > 0.1, Table 2).There was no significant difference in FEV1,
FVC, FEV1/FVC, mMRC, and Borg parameter between each group (p-
value > 0.1, Table 3). The sequence of the drug administration had no
significant effect on the efficacy of the combination therapy (Table 3).
3.1. Outcome
Since we selected the stable COPD patents as defined: patient who
clinically is stable with no exacerbations or hospital admissions in the
last 6 month, so the patents were in fairly good general condition,
during the course of protocol was well, all of them were discharged
from hospital with good condition.
4. Discussion
COPD patients are more susceptible to postoperative complication
after thoracic surgery (8) stabilization helps them decrease the re-
spiratory disability and physical activity-related breathlessness (6.7).
Conventional treatment options for COPD patients include admin-
istration of β2-agonist, anticholinergic, and glucocorticosteroid agents.
More investigation is needed to define the optimal mode of pharma-
cotherapy in this group of patients [27,28]. Nebulized furosemide
provides an additional therapeutic option to alleviate dyspnea and
other physiologic respiratory parameters in COPD exacerbation.
There is increasing evidence suggesting that nebulized furosemide
could be an option as single or combination therapy with Nebulized
salbutamol. The effectiveness of nebulized furosemide in decreasing
airflow obstruction in acute asthma exacerbation also has been reported
[29–31].
Our study suggest that the result of administration of either drugs as
single therapy was not significantly different in the terms of spirometric
indices and mMRC and Borg results. So nebulized furosemide is as ef-
fective as nebulized salbutamol as a known standard drug for COPD
treatment and can alleviate dyspnea and other physiologic respiratory
parameters, without any cardiovascular comorbidity or arrhythmias
which may be seen salbutamol [32]. We had considerable results with
the use of combination therapy with significant improvement of FEV1,
FVC, FEV1/FVC, MMRC, and Borg parameters in both groups when
compared to the baseline (p-value < 0.001), there was no difference if
either drug was added to the single therapy with other drug and the
results in either case was similar.
The result of our study with a significant bronchodilatory effect in
stable COPD is similar to a study by Hojat et al. that showed 40 mg
nebulized furosemide as an adjunct to the conventional treatments
improved significantly the FEV1, dyspnea, pH, mean blood pressure,
and heart rate in patients with COPD exacerbation [33], another study
with the same results was reported in children with mild asthma [34].
This study is line with several other studies which demonstrated that
inhalation of nebulized furosemide (40 mg) compared with nebulized
0.9% saline decreased intensity ratings of breathlessness provoked by a
variety of respiratory stimuli at rest in healthy adults or by constant-
load cycle endurance exercise testing in COPD patient [35–39]. In a
study by Ong KC et al., the effect of inhaled furosemide on dyspneic
sensation during exercise testing with placebo has been investigated.
They showed a significant improvement in mean FEV1 and FVC after
inhalation of furosemide (p = 0.038 and 0.005, respectively) but not
after placebo, and they conclude that inhalation of furosemide alle-
viates the sensation of dyspnea induced by constant-load exercise
testing in patients with COPD and that there is significant bronchodi-
lation after inhalation of furosemide compared with placebo in these
patients [40].
Table 1
Demographics of the enrolled participants.
Groups Frequency Sex Age (years)
Male Female Mean SD
Group I 34 27 7 67.26 10.09
Group II 35 28 7 62.65 12.83
Total 69 55 14 64.92 11.71
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In the above-mentioned study, it has been showed that nebulized
furosemide have a positive influence on dyspnea. They assessed the
superiority of nebulized furosemide plusplacebo versus nebulized sal-
butamol. In our study we assessed the effect of combination therapy
with single therapy by sequentially adding one regimen to another.
Although the role of furosemide used as an adjunctive treatment for
acute asthma and COPD exacerbation is an improving issue [29–31],
some other studies have reported an inert effect for nebulized fur-
osemide [41–43].
Despite extensive investigation, the mechanisms underlying relief of
breathlessness with nebulized furosemide has not yet been understood.
Several mechanisms have been suggested for anti-dyspneic action of
nebulized furosemide including a direct protective impact on airways in
addition to a protective effect against cholinergic, non-cholinergic, and
non-adrenergic contraction of smooth muscles, the latter action pro-
viding an increased vascular response, improving micro vascular
leakage to counteract evaporation of water, and vasodilatation [44,45].
In fact, the anti-asthmatic performance of furosemide is not only related
to its effects as a diuretic agent, but also to the ability of dilating airway
vasculature leading to increase of blood flow that supplying lung tissue
[46].
The therapeutic effect of nebulized furosemide is more than its oral
intake which leads to an increased diuresis via transmission of sodium,
potassium, and chlorine ions in the ascending limb of the Henle loop
[29]. Nebulized furosemide has a direct protective effect on the airway
[47,48]. It even improves dyspnea in cancer patients [49]). Other me-
chanisms have been proposed in both animal and human studies
e.g.prolonging the breath-holding time and alleviating respiratory dis-
comfort in healthy volunteers [50], changing the activity of pulmonary
stretch receptors (PSRs) which provide sensory feedback information
on lung expansion via the vagus nerve to cortical and sub cortical re-
gions of the brain which in turn may be implicated in the perception of
breathlessness [51,52].
Our cases were stable COPD patients that may not resemble the
general population, however, they were really the patients who were
not in exacerbation, but had dyspnea in their daily activities.
Overall, these findings suggest that combination therapy can be a
viable option in stable COPD patients. This combination therapy may
have possible synergistic effect or adjunctive effect, yet optimizing the
combination measure still needs to me more investigated in future.
5. Conclusion
Nebulized furosemide is as effective as nebulized salbutamol in
stable COPD treatment. Adding nebulized furosemide to nebulized
salbutamol in such patients significantly improves spirometry indices
and relieves dyspnea more than single therapy without any side effect.
But optimization of the drugs’ dose require to be designed in future
studies.
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Table 2
Comparison of the drugs’ effects as pulmonary functional parameters within groupsa.
Group Index Baseline 1st episode 2nd episode p-valueb p-valuec
Group I FEV1 (L) 1.30 ± 0.58 1.33 ± 0.60 1.65 ± 0.76 0.30 0.001
FVC (L) 2.20 ± 0.84 2.17 ± 0.88 2.63 ± 1.07 0.180 0.001
EV1/FVC (%) 59.64 ± 16.00 60.68 ± 13.80 63.06 ± 14.4 0.175 0.019
MMRC 2.35 ± 1.20 2.05 ± 1.20 0.79 ± 1.12 0.10 0.001
Borg 7.38 ± 2.50 6.82 ± 2.34 3.56 ± 2.63 0.001 0.001
Group II FEV1 (L) 1.38 ± 0.75 1.40 ± 0.75 1.77 ± 0.90 0.21 0.001
FVC (L) 2.37 ± 1.10 2.31 ± 1.10 2.86 ± 1.32 0.041 0.001
EV1/FVC (%) 57.65 ± 16.13 58.48 ± 15.94 3.06 ± 14.86 0.270 0.001
MMRC 2.11 ± 1.15 2.00 ± 1.23 0.60 ± 1.06 0.103 0.001
Borg 7.82 ± 2.47 7.40 ± 2.41 3.43 ± 2.21 0.001 0.001
a All values presented as means ± SD.
b Comparing baseline to the 1st episode.
c Comparing baseline to the 2nd episode.
Table 3
A comparison of the drugs’ effects on pulmonary functional parameters between
groups.





FEV1 (L) 1st episodes 1.33 ± 0.60 1.40 ± 0.75 0.84
2nd episodes 1.65 ± 0.76 1.77 ± 0.90 0.59
FVC (L) 1st episodes 2.17 ± 0.88 2.31 ± 1.10 0.56
2nd episodes 2.63 ± 1.07 2.86 ± 1.32 0.56
FEV1/FVC 1st episodes 60.68 ± 13.80 58.48 ± 15.94 0.84
2nd episodes 63.06 ± 14.45 63.06 ± 14.86 0.27
mMRC 1st episodes 2.00 ± 1.23 2.00 ± 1.23 0.16
2nd episodes 0.79 ± 1.12 0.60 ± 1.06 0.87
Borg 1st episodes 6.82 ± 2.34 7.40 ± 2.41 0.45
2nd episodes 3.56 ± 2.63 3.43 ± 2.21 0.28
a Independent sample T test for comparison of means between two groups.
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then by this study we assessed dyspnea which was sensed by patients in
exertion every day.
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